Ty - Jour A2 - Annibale，Bruno Au - Steinmetz，Tilman Au - Schröder，Jan Au - Plath，Margarete Au - Link，Hartmut Au - Vogt，MichèleAu - Frank，Melanie Au - Marschner，Norbert Py - 2016年/02/04 TI - 癌症患者的抗癌治疗德国常规实践：从预期队列研究中的数据 - 肿瘤贫血登记处SP - 8057650 VL - 2016年AB - 这项前瞻队列研究的目的是评估目前癌症患者的抗癌治疗在德国常规实践中，包括诊断，治疗和生活质量（QOL）。88研究网站在血红蛋白（HB）水平<11g / dL（女性）或<12g / dl（男性）开始时招募了1018名患者。患者随访12周。63％的患者具有无法操作的固体肿瘤，22％可操作的固体肿瘤，和15％的血液恶性肿瘤。超过85％的接受化疗。中位年龄为67岁;48％是男性。红细胞输血（RBCTX）给予所有患者的59％，并在观察期的第1天（第1天治疗第1天）的患者的59％患者。 Erythropoiesis-stimulating agents (ESAs) were the second most frequently applied day 1 treatment (20%), followed by intravenous (IV) iron (15%) and ESA + IV iron (6%). Only about a third of patients were tested for blood serum iron parameters at the start of treatment. Overall, more than half of the patients had long-term responses to antianemic therapy. Our data suggest that in routine practice diagnostics for treatable causes of anemia are underused. A high proportion of cancer patients receive RBCTx. It should be discussed whether thorough diagnostics and earlier intervention could decrease the need for RBCTx. This trial is registered with NCT01795690.。SN - 2090-1267 UR - https://doi.org/10.1155/2016/8057650 do - 10.1155/2016 / 8057650 jf - 贫血pb - Hindwi Publishing CorporationKW - ER -